Status:
COMPLETED
Description of the Impact of Symptoms on Quality of Life in HHT Disease: DISQUO
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Hereditary Hemorrhagic Telangiectasia (HHT)
Eligibility:
All Genders
18+ years
Brief Summary
In 2017, the ELECT-RO study led, firstly, to the creation of a tool to measure quality of life (QoL) specific to HHT (hereditary haemorrhagic telangiectasia disease), QoL-HHT, based on patients' exper...
Eligibility Criteria
Inclusion
- Patient with clinically (presence of at least 3 Curaçao criteria) and/or molecularly confirmed HHT disease
- Patient of legal age (over 18 years old)
- Patient who has received the information and has not objected to taking part in the study
Exclusion
- Patients unable to read a questionnaire written in French
- Adults protected by law
Key Trial Info
Start Date :
December 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2025
Estimated Enrollment :
185 Patients enrolled
Trial Details
Trial ID
NCT07191639
Start Date
December 1 2024
End Date
May 1 2025
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Femme-Mère-Enfant - Centre de référence pour la maladie de Rendu-Osler
Bron, France, 69500